You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Byetta Articles
Popular Byetta Articles
Highly Recommended Byetta Articles
Send a link to this page to your friends and colleagues.
Amylin Reports Quarterly Loss Due to Costs of Developing a Once-Weekly Form of Byetta
San Diego-based Amylin Pharmaceuticals, Inc., posted a second-quarter loss of $64.8 million, or 47 cents per share. This compares to a 2007 second-quarter loss of 45 million, or 34 cents a share.
The per-share loss was two cents below what Wall Street analysts had predicted.
Byetta (exenatide), which has been on the market since 2005, has become a popular twice-daily treatment for glucose control. Its beneficial side effects include significant weight loss and lowered A1c’s, as well as appetite control.
Amylin is now spending significant sums on the creation of a once-weekly form of the drug, which is now in Phase 3 trials. The company plans to apply for final FDA approval of the drug by this time next year.
Second-quarter sales of Byetta reached $177.5 million—about 79 percent of the company’s total of $224.3 million in revenues. Research costs in the same period amounted to $75.4 million, while overall sales, management, and administrative costs reached $111 million.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.